Sinovac's combined hepatitis A and B vaccine, Beirlaifu, is re-registered for market launch
Beijing Kexing Holdings Co., Ltd. subsidiary Beijing Kexing Biological Products Co., Ltd. independently developed the combined hepatitis A and B vaccine Beirlaifu, which has obtained the drug re-registration approval notice, making it the only combined hepatitis A and B vaccine approved for sale in China
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments